02:17 PM EDT, 03/16/2026 (MT Newswires) -- Novartis ( NVS ) subsidiary Novartis Capital filed a prospectus with the US Securities and Exchange Commission on Monday for eight tranches of notes to repay a bridge loan used to finance the acquisition of Avidity Biosciences

The notes have maturities from 2029 to 2056 and will be fully and unconditionally guaranteed by Novartis ( NVS ), the filing said.

Novartis ( NVS ) agreed to buy Avidity in October for $12 billion.

Price: 154.50, Change: +1.06, Percent Change: +0.69